Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune Cell Function and Interaction, and Immunotherapy and Immune Responses.
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Design of a potent interleukin-21 mimic for cancer immunotherapy
An esophagus cell atlas reveals dynamic rewiring during active eosinophilic esophagitis and remission
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
Immune mechanisms of toxicity from checkpoint inhibitors
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
Antigen identification and high-throughput interaction mapping by reprogramming viral entry
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Human differentiated eosinophils release IL-13 in response to IL-33 stimulation
IFNγ from IL-12 virotherapy stably controls tumors independent of T cell cytotoxicity and IFNγ sensing by tumor cells
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
Immune receptor inhibition through enforced phosphatase recruitment
Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
CoVA: An Acuity Score for Outpatient Screening that Predicts Coronavirus Disease 2019 Prognosis
De novo design of potent and selective mimics of IL-2 and IL-15
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities